Investment Rating - The report maintains a "Positive" outlook for the pharmaceutical industry, expecting overall returns to exceed the CSI 300 Index by more than 5% in the next six months [1][10]. Core Insights - As of December 20, 2024, the pharmaceutical sector showed a performance increase of +0.39%, outperforming the CSI 300 Index by 0.84 percentage points, ranking 8th among 31 sub-industries in the Shenwan classification [2]. - Among sub-industries, offline pharmacies (+1.09%), vaccines (+0.85%), and pharmaceutical distribution (+0.70%) performed well, while medical devices (-0.36%), other biological products (-0.34%), and blood products (-0.08%) lagged behind [2]. - Key stocks included Hanyu Pharmaceutical (+12.21%), Rejing Biological (+11.69%), and Lukan Pharmaceutical (+10.06%) on the gainers' list, while Hulukids (-5.69%), Kain Technology (-5.02%), and Lingkang Pharmaceutical (-4.78%) were among the biggest losers [2]. Sub-industry Ratings - Chemical pharmaceuticals: No rating - Traditional Chinese medicine: Neutral - Biopharmaceuticals II: Neutral [2]. Company News - Merck announced that two key Phase 3 trials (MK-8591A-051 and MK-8591A-052) achieved their primary endpoints, demonstrating non-inferiority compared to the control antiviral therapy for HIV-1 infected adults [2]. - Zhaoyan New Drug (603127) plans to establish a partnership with Huaxia Equity Investment to develop the Alpha targeted therapy industry chain, aiming to raise 203 million RMB [2]. - Bidu Pharmaceutical (688073) announced a stock incentive plan for 65 individuals, including executives, with a total of 255,400 restricted shares to be granted [2].
医药行业周报：默沙东口服HIV疗法达两项关键3期试验主要终点
Tai Ping Yang·2024-12-23 05:42